TABLE 3.
Standardized incidence ratios of different types of malignancies in kidney transplant patients by sex.
| Cancer site | ICD-10 | Male patients | Female patients | All | |||
|---|---|---|---|---|---|---|---|
| O/E | SIR (95% CI) | O/E | SIR (95% CI) | O/E | SIR (95% CI) | ||
| Prostate | C61 | 9/1.109145 | 8.11 (3.71, 15.4)* | ||||
| Breast | C50 | 8/5.166225 | 1.56 (0.67, 3.08) | ||||
| Ovary | C56 | 1/0.7406286 | 1.35 (0.36, 5.07) | ||||
| Cervix | C53 | 3/1.728333 | 1.73 (0.86, 4.91) | ||||
| Bronchus, lung, trachea | C33, C34 | 5/4.185616 | 1.20 (0.39, 2.79) | 1/1.232264 | 0.81 (0.02, 4.52) | 6/5.41788 | 1.11 (0.41, 2.41) |
| Stomach | C16 | 1/0.8211308 | 1.22 (0.03, 6.79) | 0/0.4394963 | 0.0 (0.0, 6.82) | 1/1.260627 | 0.79 (0.02, 4.42) |
| Liver and bile duct | C22, C24 | 5/6.909814 | 0.73 (0.24, 1.55) | 4/1.381054 | 2.90 (0.79, 7.42) | 9/8.290868 | 1.09 (0.50, 2.06) |
| Gallbladder | C23 | 1/0.0948561 | 10.5 (0.27, 58.7) | 0/0.0948561 | 0 (0.0, 27.1) | 1/0.2053207 | 4.87 (0.12, 27.1) |
| Colorectal | C18 - C20 | 2/3.178986 | 0.63 (0.08, 2.27) | 4/1.370327 | 2.92 (0.80, 7.47) | 6/4.549313 | 1.32 (0.48, 2.87) |
| Kidney | C64 | 3/0.2353302 | 12.7 (2.63, 37.3)* | 0/0.0575237 | 0.0 (0.0, 52.1) | 3/0.2928539 | 10.2 (2.11, 29.9)* |
| Urothelial | C65 - C67 | 11/0.6300718 | 17.5 (8.72, 31.2)* | 17/0.1482415 | 114.7 (66.8, 183.6)* | 28/0.6227172 | 36.0 (23.9, 52.0)* |
| Thyroid | C73 | 0/0.2594859 | 0 (0.0, 11.5) | 2/0.5199386 | 3.85 (0.47, 13.9) | 2/0.7794246 | 2.57 (0.31, 9.27) |
| Uterus, part unspecified | C55 | 1/0.0882458 | 11.3 (0.29, 63.1) | ||||
| Other solid malignancies: unspecified | O & U | 1/1.03719 | 0.96 (0.02, 5.37) | 1/0.3765939 | 2.66 (0.07, 14.8) | 2/1.413784 | 1.42 (0.17, 5.11) |
| All solid malignancies | 38/18.461626 | 2.06 (1.46, 2.83)* | 42/13.343727 | 3.15 (2.27, 4.26)* | 80/31.805353 | 2.52 (1.99, 3.13)* | |
| NHL** | C82-85, C96 | 18/0.9139875 | 19.7 (11.7, 31.1)* | 11/0.5157974 | 21.3 (10.6, 38.2)* | 29/1.429785 | 20.3 (13.6, 29.1)* |
| HL | C81 | 1/0.0270835 | 36.9 (0.94, 205.7) | 0/0.0121523 | 0 (0.0, 246.5) | 1/0.0392358 | 25.5 (0.65, 142.0) |
| Leukemia | C91, C92-C94 | 1/0.3327671 | 3.01 (0.08, 16.7) | 1/0.136444 | 7.33 (0.19, 40.8) | 2/0.4692111 | 4.26 (0.52, 15.4) |
| All hematologic malignancies | 20/1.2738381 | 15.7 (9.59, 24.2)* | 12/0.6643937 | 18.1 (9.33, 31.6)* | 32/1.9382318 | 16.5 (11.3, 23.3)* | |
| Non-melanoma skin cancer*** | C44 | 16/0.5000404 | 32.0 (18.3, 52.0)* | 5/0.3501561 | 14.3 (4.64, 33.3)* | 21/0.8501965 | 24.7 (15.3, 37.8)* |
| All solid and hematologic malignancies | 58/19.735464 | 2.94 (2.23, 3.80)* | 54/14.008121 | 3.86 (2.90, 5.03)* | 112/33.743585 | 3.32 (2.73, 3.99)* | |
| All cancers | 74/20.235504 | 3.66 (2.87, 4.59)* | 59/14.358277 | 3.76 (2.82, 4.91)* | 133/34.593781 | 3.85 (3.22, 4.56)* | |
Notes: *Significant results at 95% confidence interval. ** Includes monomorphic B cells, and polymorphic, monomorphic T cells. *** Includes squamous cell carcinoma and basal cell carcinoma. The total risk time for the cohort was 16,495 person-years for standardized incidence ratio calculations.
Abbreviations: CI, confidence interval; E, expected; HL, Hodgkin’s lymphoma; ICD-10, international classification of diseases 10; NHL, non-Hodgkin’s lymphoma; O, observed; SIR, standardized incidence ratio.